Skip to Main Content
 

Global Search Box

 
 
 
 

Files

File List


Ogunwumi PDF A APPROVED.pdf (985.42 KB)

ETD Abstract Container

Abstract Header

The Development of Monoclonal Antibodies Against Human Immunodeficiency Virus-1 Viral Protein R Using Hybridoma Technology

Ogunwumi, Olumide Babatope
http://rave.ohiolink.edu/etdc/view?acc_num=ysu1441377756

Abstract Details

2015, Master of Science in Biological Sciences, Youngstown State University, Department of Biological Sciences and Chemistry.
Hybridoma technology allows the development of monoclonal antibodies that are specific to a target antigen. The goal of this project was to use hybridoma technology to develop monoclonal antibodies that would be able to recognize and bind both cell bound HIV-1 Viral protein r (Vpr) and cell free HIV-1 Vpr. A mouse was immunized with Vpr antigen and the spleen from the immunized mouse was isolated and teased in order to release antibody-secreting spleen cells. Isolated spleen cells were fused with myeloma cells using polyethylene glycol and then cultured in HAT medium in order to select for hybridomas. Hybridomas secreting anti-HIV-1 Vpr were screened by indirect ELISA. About 70 % of the hybridoma cell lines were able to recognize and bind to the Vpr antigen. Antibodies from DL.VPR.D1 had the best amount of binding to the Vpr antigen when compared to the positive control. The antibodies from DL.VPR.D1 were isotyped in order to determine what class of antibody they belong to. Non-specific binding of the negative control was noticed during isotyping. The use of casein blocking buffer helped in eliminating the non-specific binding. It was found that the antibodies from DL.VPR.D1 belong to the IgG2b class. DL.VPR.D1 was further subcloned by limiting dilution in order to develop monoclonal cells. Seven subclones were derived from DL.VPR.D1. Three of the seven subclones were positive with DL.VPR.D1.G6 having the highest amount of binding to Vpr antigen. Over time DL.VPR.D1.G6 antibodies lost its binding abilities of the HIV-1 Vpr antigen. Loss of reactivity to Vpr antigen was also noticeable in some of the subclones from cell lines (EH.VPR.C5.C6, DF.VPR.C4.D12) that were initially reactive to the Vpr. Amidst the shortcomings; this study demonstrates the importance of hybridoma technology in developing antibodies against a specific target.
Diana Fagan, PhD (Advisor)
Jonathan Caguiat, PhD (Committee Member)
Heather Lorimer, PhD (Committee Member)
95 p.
Immunology; Microbiology; Virology
HIV-1; VPR; Hybridoma Technology; Monoclonal Antibodies

Recommended Citations

Citations

  • Ogunwumi, O. B. (2015). The Development of Monoclonal Antibodies Against Human Immunodeficiency Virus-1 Viral Protein R Using Hybridoma Technology [Master's thesis, Youngstown State University]. OhioLINK Electronic Theses and Dissertations Center. http://rave.ohiolink.edu/etdc/view?acc_num=ysu1441377756

    APA Style (7th edition)

  • Ogunwumi, Olumide. The Development of Monoclonal Antibodies Against Human Immunodeficiency Virus-1 Viral Protein R Using Hybridoma Technology . 2015. Youngstown State University, Master's thesis. OhioLINK Electronic Theses and Dissertations Center, http://rave.ohiolink.edu/etdc/view?acc_num=ysu1441377756.

    MLA Style (8th edition)

  • Ogunwumi, Olumide. "The Development of Monoclonal Antibodies Against Human Immunodeficiency Virus-1 Viral Protein R Using Hybridoma Technology ." Master's thesis, Youngstown State University, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=ysu1441377756

    Chicago Manual of Style (17th edition)

ysu1441377756
1,689
© 2015, all rights reserved.
This open access ETD is published by Youngstown State University and OhioLINK.